Positron emission tomography combined with computed tomography (PET/CT) is currently the standard imaging method in neuro-oncology for gliomas and metastatic lesions. There is much less experience with the use of PET/CT in meningioma, the most common primary tumor of the central nervous system, and there are some differences in how results are interpreted. The aim of the present work was to assess the potential for and features of the use of PET/CT to determine the degree of malignancy of meningioma, its prevalence, responses to radiotherapy, and diagnosis of relapse and/or post-radiation changes based on our own clinical experience and review of the literature. The study included 70 patients with 77 meningiomas who underwent 11C-methionine PET/CT. Mean age at investigation was 57.4 years (range 19–86 years). The main parameter evaluated, the tumor/normal ratio (T/N) of 11C-methionine (11C-MET) in tumors, averaged 3.13 (1.00–10.66). Meningiomas had high 11C-MET T/N, with values of >1.5 in 89.6% of cases. In histologically verified malignancy grade 1, 2, and 3 meningiomas (WHO scale), median T/N values were 4.06 [3.04; 4.57], 2.32 [2.12; 3.69], and 4.29 [2.60; 5.10] respectively, with no significant between-group differences. At the same time, non-growing or slowly growing histologically unverified meningiomas, i.e., incidentally discovered, had significantly lower 11C-MET T/N than grade 1 and 3 meningiomas. There was no significant difference in T/N between irradiated meningiomas with controls for tumor growth (3.81 [2.97, 3.98]) and relapse (3.62 [2.60, 4.30]). Comparison of irradiated and non-irradiated grade 1, 2, and 3 meningiomas, as well as the combined group of grade 1–3 tumors, revealed no significant differences in 11C-MET T/N. The use of PET/CT for meningiomas has a number of important characteristics. Meningiomas had high 11C-MET T/N. Our data indicate that 11C-MET PET/CT does not distinguish between meningiomas with different degrees of malignancy, i.e., WHO grades 1, 2, and 3. 11C-MET T/N in meningiomas remains stably high or shows a slight decrease in cases with effective radiotherapy and long-term local control. Comparison of growing and non-growing meningiomas revealed no significant differences in 11C-MET T/N between irradiated and non-irradiated tumors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Acker, G., Kluge, A., Lukas, M., et al., “Impact of 68Ga-DOTATOC PET/ MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution,” Neurosurg. Focus, 46, No. 6, E9 (2019).
Afshar-Oromieh, A., Giesel, F. L., Linhart, H. G., et al., “Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI,” Eur. J. Nucl. Med. Molecule. Imag., 39, No. 9, 1409–1415 (2012).
Arita, H., Kinoshita, M., Okita, Y., et al., “Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography,” J. Neurooncol., 107, No. 2, 379– 386 (2012).
Astner, S. T., Dobrei-Ciuchendea, M., Essler, M., et al., “Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas,” Int. J. Radiat. Oncol. Biol. Phys., 72, No. 4, 1161–1167 (2008).
Campos Neto, G. d. C., Amaro Junior, E., Weltman, E., et al., “Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas,” Einstein (Sao Paulo), 20eAO0104 (2022).
Cremerius, U., Bares, R., Weis, J., et al., “Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET,” J. Nucl. Med., 38, No. 1, 26–30 (1997).
Filippi, L., Palumbo, I., Bagni, O., et al., “Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: A systematic review of the literature,” Diagnostics (Basel), 12, No. 7) (2022).
Grosu, A.-L., Weber, W. A., Astner, S. T., et al., “11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy,” Int. J. Radiat. Oncol. Biol. Phys., 66, No. 2, 339–344 (2006).
Gudjonsson, O., Blomquist, E., Lilja, A., et al., “Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET,” Eur. J. Nucl. Med., 27, No. 12, 1793–1799 (2000).
Hua, L., Hua, F., Zhu, H., et al., “The diagnostic value of using 18F-fluorodeoxyglucose positron emission tomography to differentiate between low- and high-grade meningioma,” Cancer Manag. Res., 11, 9185–9193 (2019).
Ivanidze, J., Roytman, M., Lin, E., et al., “Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas,” J. Neuroimaging, 29, No. 5, 650–656 (2019).
Jeltema, H.-R., Jansen, M. R., Potgieser, A. R. E., et al., “Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY),” Neuroradiology, 63, No. 11, 1791–1799 (2021).
Jung, I.-H., Chang, K. W., Park, S. H., et al., “Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma,” Sci. Rep., 12, No. 1, 13663 (2022).
Kaul, D., Budach, V., Wurm, R., et al., “Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma,” Radiat. Oncol., 9, 78 (2014).
Kessel, K. A., Weber, W., Yakushev, I., et al., “Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome,” Eur. J. Nucl. Med. Mol. Imaging, 47, No. 6, 1391–1399 (2020).
Kowalski, E. S., Khairnar, R., Gryaznov, A. A., et al., “68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas,” Radiat. Oncol., 16, No. 1, 151 (2021).
Kriwanek, F., Ulbrich, L., Lechner, W., et al., “Impact of SSTR PET on inter-observer variability of target delineation of meningioma and the possibility of using threshold-based segmentations in radiation oncology,” Cancers (Basel), 14, No. 18 (2022).
Lee, J. W., Kang, K. W., Park, S.-H., et al., “18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma,” Eur. J. Nucl. Med. Mol. Imaging, 36, No. 10, 1574–1582 (2009).
Lütgendorf-Caucig, C., Pelak, M., Flechl, B., et al., “The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy,” Strahlentherapie und Onkologie, 199, No. 4, 396–403 (2023).
Mitamura, K., Yamamoto, Y., Norikane, T., et al., “Correlation of 18F-FDG and 11C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas,” Ann. Nucl. Med., 32, No. 9, 627–633 (2018).
Palmisciano, P., Watanabe, G., et al., “The role of 68GaGa-DOTA-SSTR PET radiotracers in brain tumors: A systematic review of the literature and ongoing clinical trials,” Cancers (Basel), 14, No. 12 (2022).
Perlow, H. K., Siedow, M., Gokun, Y., et al., “68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma,” Int. J. Radiat. Oncol. Biol. Phys., 113, No. 4, 859–865 (2022).
Rachinger, W., Stoecklein, V. M., Terpolilli, N. A., et al., “Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue,” J. Nucl. Med., 56, No. 3, 347–353 (2015).
Rogers, L., Barani, I., Chamberlain, M., et al., “Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review,” J. Neurosurg., 122, No. 1, 4–23 (2015).
Ryttlefors, M., Danfors, T., Latini, F., et al., “Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography,” Eur. J. Nucl. Med. Mol. Imaging, 43, No. 8, 1432–1443 (2016).
Slot, K. M., Verbaan, D., Buis, D. R., et al., “Prediction of meningioma WHO grade using PET findings: A systematic review and meta-analysis,” J. Neuroimaging, 31, No. 1, 6–19 (2021).
Verger, A., Kas, A., Darcourt, J., and Guedj, E., “PET imaging in neuro-oncology: An update and overview of a rapidly growing area,” Cancers (Basel), 14, No. 5 (2022).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Vysshei Nervnoi Deyatel’nosti imeni I. P. Pavlova, Vol. 74, No. 1, pp. 60–68, January–February, 2024.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Galkin, M.V., Vikhrova, N.B., Golanov, A.V. et al. 11C-Methionine PET/CT in Meningioma. Neurosci Behav Physi 54, 894–899 (2024). https://doi.org/10.1007/s11055-024-01673-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-024-01673-z